Clinical Trial Update: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate the safety and antiviral activity of IDX184 in combination with pegylated interferon and ribavirin over 12 weeks for chronic hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IDX184 (IDX184)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED